Ruxolitinib for Cancer Cachexia

Part of paid clinical trials in Dallas, Texas.

Sponsor
Tu Dan
Study ID
NCT04906746
Phase
EARLY_PHASE1
Status
Active Not Recruiting

Conditions

  • Cachexia
  • Stage IV Non-small Cell Lung Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

To assess toxicity with use of Ruxolitinib in NSCLC cachexia patients; to associate levels of JAK/STAT signaling in blood, adipose, and muscle pre- and post-ruxolitinib treatment with changes in cachexia and anorexia.

Key Dates

Start date
Feb 23, 2022
Status verified
Jul 2025
Primary completion
Sep 27, 2024
Completion
Dec 31, 2025

Study Design

Enrollment
10 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Dosing Regimen for Ruxolitinib
    Level 0: Ruxolitinib 0 MG po bid for 1 month (Month 1) Level 1: Ruxolitinib 10 MG po bid for 1 month (Month 2) Level 2: Ruxolitinib 15 MG po bid for 1 month (Month 3)

Primary Outcome Measure

Number of non-small cell lung cancer cachexia patients with toxicity with the use of Ruxolitinib [ Time Frame: 3 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
UT Southwestern Medical CenterDallasTexas75390-

Find similar trials in Dallas, TX

By research site
UT Southwestern Medical Center· Dallas, TX

Related Studies